Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.

Abdominal radiology (New York)

Gauthier ID, Macleod CA, Sathiadoss P, McGrath TA, Nair V, Schieda N.
PMID: 34997298
Abdom Radiol (NY). 2022 Jan 07; doi: 10.1007/s00261-021-03367-3. Epub 2022 Jan 07.

OBJECTIVES: Gadoxetic acid (GA) is a half-biliary excreted gadolinium-based contrast agent (GBCA) administered at lower dose than gadobenic acid with similar ionic structure. Gadobenic acid is considered low-risk for nephrogenic systemic fibrosis (NSF) in patients with impaired renal function;...

Cite
Gauthier ID, Macleod CA, Sathiadoss P, et al. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment. Abdom Radiol (NY). 2022;doi: 10.1007/s00261-021-03367-3.
Gauthier, I. D., Macleod, C. A., Sathiadoss, P., McGrath, T. A., Nair, V., & Schieda, N. (2022). Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment. Abdominal radiology (New York), . https://doi.org/10.1007/s00261-021-03367-3
Gauthier, Isabelle Danika, et al. "Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment." Abdominal radiology (New York) vol. (2022). doi: https://doi.org/10.1007/s00261-021-03367-3
Gauthier ID, Macleod CA, Sathiadoss P, McGrath TA, Nair V, Schieda N. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment. Abdom Radiol (NY). 2022 Jan 07; doi: 10.1007/s00261-021-03367-3. Epub 2022 Jan 07. PMID: 34997298.
Copy Download .nbib Format: NLM
Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure.

European radiology

Liu C, Shen Z, Ma H, Wang X, Wang X, Liu K, Wang X, Zhu Q, Zhao X.
PMID: 34989839
Eur Radiol. 2022 Jan 06; doi: 10.1007/s00330-021-08440-5. Epub 2022 Jan 06.

OBJECTIVES: To determine the value of gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging (MRI) from the hepatobiliary phase for predicting poor outcome in acute-on-chronic liver failure (ACLF) patients.METHODS: In this single-center retrospective study, 74 patients diagnosed as ACLF who underwent...

Cite
Liu C, Shen Z, Ma H, et al. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. Eur Radiol. 2022;doi: 10.1007/s00330-021-08440-5.
Liu, C., Shen, Z., Ma, H., Wang, X., Wang, X., Liu, K., Wang, X., Zhu, Q., & Zhao, X. (2022). Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. European radiology, . https://doi.org/10.1007/s00330-021-08440-5
Liu, Chenxi, et al. "Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure." European radiology vol. (2022). doi: https://doi.org/10.1007/s00330-021-08440-5
Liu C, Shen Z, Ma H, Wang X, Wang X, Liu K, Wang X, Zhu Q, Zhao X. Gd-BOPTA-enhanced hepatobiliary phase MR imaging can predict the prognosis of patients with acute-on-chronic liver failure. Eur Radiol. 2022 Jan 06; doi: 10.1007/s00330-021-08440-5. Epub 2022 Jan 06. PMID: 34989839.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries